SCHEMBL2819635

SCHEMBL2819635

CN(Cc1ccc(F)cc1F)[C@H]1C[C@@H](C(=O)O)N(Cc2cccc(Cl)c2)C1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 2/20 0.39
HTT P42858 2/20 0.39
RORC P51449 1/20 0.39
SIGMAR1 Q99720 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAOA P21397 4/20 0.37
MAOB P27338 4/20 0.37
AGTR2 P50052 3/20 0.37
CACNA1G O43497 2/20 0.37
MC1R Q01726 1/20 0.37
S1PR1 P21453 1/20 0.37
S1PR5 Q9H228 1/20 0.37
CCR5 P51681 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3635161 1.00 MEN1 (0.41) MEN1KMT2AL3MBTL1KDM4EHTT
SCHEMBL2822223 0.91 MEN1 (0.40) MEN1KMT2AL3MBTL1KDM4EHTT
SCHEMBL3633815 0.88 S1PR1 (0.44) RORCSIGMAR1AGTR2S1PR1S1PR5
SCHEMBL2820787 0.88 S1PR1 (0.44) RORCSIGMAR1AGTR2S1PR1S1PR5
SCHEMBL3640878 0.83 KMT2A (0.45) MEN1KMT2AL3MBTL1KDM4EHTT
SCHEMBL2820989 0.83 KMT2A (0.45) MEN1KMT2AL3MBTL1KDM4EHTT
SCHEMBL2820344 0.82 DPP4 (0.41) KDM4ERORCCACNA1G
SCHEMBL2817101 0.81 TACR1 (0.42) MEN1KMT2AKDM4EHTTALDH1A1
SCHEMBL2822326 0.79 ALDH1A1 (0.39) L3MBTL1KDM4EHTTRORCALDH1A1
SCHEMBL3639016 0.79 ALDH1A1 (0.39) L3MBTL1KDM4EHTTRORCALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155672-B1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-10-27 EP disclosed
EP-2155672-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-02-24 EP disclosed
US-7528136-B2 for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
WO-2008148689-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-12-11 WO disclosed
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS SLC6A3, OPRL1, OPRK1 MEN1 4786/4885KMT2A 1350/4885L3MBTL1 4509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.